Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498668 | 0.89 | GSK3B (0.49) | GSK3BSIGMAR1NPC1RAB9AMAPT | |
| SCHEMBL4484533 | 0.86 | GSK3B (0.38) | GSK3BCYP2D6 | |
| SCHEMBL4480418 | 0.86 | GSK3B (0.58) | GSK3BSIGMAR1 | |
| SCHEMBL4489759 | 0.84 | GSK3B (0.44) | GSK3BDRD2 | |
| SCHEMBL4497896 | 0.83 | GSK3B (0.57) | GSK3BSIGMAR1 | |
| SCHEMBL4489193 | 0.82 | GSK3B (0.43) | GSK3BSIGMAR1DRD2 | |
| SCHEMBL4492863 | 0.82 | P2RX3 (0.43) | GSK3BCYP2D6 | |
| SCHEMBL4495156 | 0.81 | GSK3B (0.47) | GSK3B | |
| SCHEMBL4587845 | 0.81 | GSK3B (0.46) | GSK3BCYP2D6 | |
| SCHEMBL4473700 | 0.79 | GSK3B (0.55) | GSK3BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608624-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives | SANOFI-AVENTIS (FR) | 2009-10-27 | — | — | US | claimed |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | claimed |
| US-7067521-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-06-27 | — | — | US | claimed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | claimed |
| EP-1184384-A1 | 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | claimed |
| US-7608624-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives | SANOFI-AVENTIS (FR) | 2009-10-27 | — | — | US | disclosed |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-7067521-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-06-27 | — | — | US | disclosed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | disclosed |
| US-20040044010-A1 | 1-[alkyl],1-[(heteroaryl)alkyl] and 1-[aryl]alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1h)-one derivatives | SANOFI (FR) | 2004-03-04 | — | — | US | disclosed |
| EP-1184384-A1 | 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044010-A1 | 1-[alkyl],1-[(heteroaryl)alkyl] and 1-[aryl]alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1h)-one derivatives | PSEN1, GSK3A, GSK3B | GSK3B 3/4885PTGDR 2912/4885SIGMAR1 372/4885 |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | PSEN1, PSEN2, SNCA | GSK3B 4408/4885PTGDR 1264/4885SIGMAR1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.